What Adapting During COVID-19 Taught Us About Innovating Drug Development

COVID-19 changed the clinical research landscape by proving the use and efficacy of DCTs, patient-centricity and adaptive designs. Dr Ubavka DeNoble, Executive Vice President of Biotech Operations and Senior Medical Officer of Parexel Biotech shares advice on how CMOs can think about leadership, change management and investing in new technologies such as artificial intelligence, improved data collection and system interoperability to improve patient recruitment and retention and drug development efficacy. Key Takeaways: How to lead with an eye on industry changes and flexibilityThe importance of rewarding innovation rather than standardizing a single approachObservations of successful change management throughout the COVID-19 pandemic